214 related articles for article (PubMed ID: 24475817)
1. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival.
Vargas HA; Wassberg C; Fox JJ; Wibmer A; Goldman DA; Kuk D; Gonen M; Larson SM; Morris MJ; Scher HI; Hricak H
Radiology; 2014 Apr; 271(1):220-9. PubMed ID: 24475817
[TBL] [Abstract][Full Text] [Related]
2. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer.
Fox JJ; Gavane SC; Blanc-Autran E; Nehmeh S; Gönen M; Beattie B; Vargas HA; Schöder H; Humm JL; Fine SW; Lewis JS; Solomon SB; Osborne JR; Veach D; Sawyers CL; Weber WA; Scher HI; Morris MJ; Larson SM
JAMA Oncol; 2018 Feb; 4(2):217-224. PubMed ID: 29121144
[TBL] [Abstract][Full Text] [Related]
3. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.
Larson SM; Morris M; Gunther I; Beattie B; Humm JL; Akhurst TA; Finn RD; Erdi Y; Pentlow K; Dyke J; Squire O; Bornmann W; McCarthy T; Welch M; Scher H
J Nucl Med; 2004 Mar; 45(3):366-73. PubMed ID: 15001675
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Positron tomographic assessment of androgen receptors in prostatic carcinoma.
Dehdashti F; Picus J; Michalski JM; Dence CS; Siegel BA; Katzenellenbogen JA; Welch MJ
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):344-50. PubMed ID: 15726353
[TBL] [Abstract][Full Text] [Related]
6. Reproducibility and Repeatability of Semiquantitative
Vargas HA; Kramer GM; Scott AM; Weickhardt A; Meier AA; Parada N; Beattie BJ; Humm JL; Staton KD; Zanzonico PB; Lyashchenko SK; Lewis JS; Yaqub M; Sosa RE; van den Eertwegh AJ; Davis ID; Ackermann U; Pathmaraj K; Schuit RC; Windhorst AD; Chua S; Weber WA; Larson SM; Scher HI; Lammertsma AA; Hoekstra OS; Morris MJ
J Nucl Med; 2018 Oct; 59(10):1516-1523. PubMed ID: 29626121
[No Abstract] [Full Text] [Related]
7. Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT.
Fox JJ; Autran-Blanc E; Morris MJ; Gavane S; Nehmeh S; Van Nuffel A; Gönen M; Schöder H; Humm JL; Scher HI; Larson SM
J Nucl Med; 2011 Nov; 52(11):1727-32. PubMed ID: 21984797
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET.
Beattie BJ; Smith-Jones PM; Jhanwar YS; Schöder H; Schmidtlein CR; Morris MJ; Zanzonico P; Squire O; Meirelles GS; Finn R; Namavari M; Cai S; Scher HI; Larson SM; Humm JL
J Nucl Med; 2010 Feb; 51(2):183-92. PubMed ID: 20080885
[TBL] [Abstract][Full Text] [Related]
9. Assessment of Simplified Methods for Quantification of
Kramer GM; Yaqub M; Vargas HA; Schuit RC; Windhorst AD; van den Eertwegh AJM; van der Veldt AAM; Bergman AM; Burnazi EM; Lewis JS; Chua S; Staton KD; Beattie BJ; Humm JL; Davis ID; Weickhardt AJ; Scott AM; Morris MJ; Hoekstra OS; Lammertsma AA
J Nucl Med; 2019 Sep; 60(9):1221-1227. PubMed ID: 30850488
[No Abstract] [Full Text] [Related]
10. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
11. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
12. Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
Sugihara T; Koizumi M; Koyama M; Terauchi T; Gomi N; Ito Y; Hatake K; Sata N
Ann Nucl Med; 2017 Dec; 31(10):719-725. PubMed ID: 28864931
[TBL] [Abstract][Full Text] [Related]
13. In vivo imaging of brain androgen receptors in rats: a [(18)F]FDHT PET study.
Khayum MA; Doorduin J; Antunes IF; Kwizera C; Zijlma R; den Boer JA; Dierckx RA; de Vries EF
Nucl Med Biol; 2015 Jun; 42(6):561-9. PubMed ID: 25735222
[TBL] [Abstract][Full Text] [Related]
14. Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis.
Morita M; Higuchi T; Achmad A; Tokue A; Arisaka Y; Tsushima Y
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1672-81. PubMed ID: 24006150
[TBL] [Abstract][Full Text] [Related]
15. 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT.
Samarin A; Hüllner M; Queiroz MA; Stolzmann P; Burger IA; von Schulthess G; Veit-Haibach P
Nucl Med Commun; 2015 Dec; 36(12):1165-73. PubMed ID: 26397999
[TBL] [Abstract][Full Text] [Related]
16. Specific
Larimer BM; Dubois F; Bloch E; Nesti S; Placzek M; Zadra G; Hooker JM; Loda M; Mahmood U
J Nucl Med; 2018 Oct; 59(10):1538-1543. PubMed ID: 29853654
[TBL] [Abstract][Full Text] [Related]
17. Serial [
Boers J; Venema CM; de Vries EFJ; Hospers GAP; Boersma HH; Rikhof B; Dorbritz C; Glaudemans AWJM; Schröder CP
Eur J Cancer; 2021 Feb; 144():151-161. PubMed ID: 33341447
[TBL] [Abstract][Full Text] [Related]
18. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
19. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Yu EY; Muzi M; Hackenbracht JA; Rezvani BB; Link JM; Montgomery RB; Higano CS; Eary JF; Mankoff DA
Clin Nucl Med; 2011 Mar; 36(3):192-8. PubMed ID: 21285676
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
